A. Benjamin Suttle

2.3k total citations
36 papers, 1.5k citations indexed

About

A. Benjamin Suttle is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, A. Benjamin Suttle has authored 36 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in A. Benjamin Suttle's work include Pancreatic and Hepatic Oncology Research (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Cancer Treatment and Pharmacology (9 papers). A. Benjamin Suttle is often cited by papers focused on Pancreatic and Hepatic Oncology Research (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Cancer Treatment and Pharmacology (9 papers). A. Benjamin Suttle collaborates with scholars based in United States, United Kingdom and Netherlands. A. Benjamin Suttle's co-authors include Jeffrey P. Hodge, Lini Pandite, Afshin Dowlati, S. Savage, Mohammed M. Dar, Herbert I. Hurwitz, Shermini Saini, D. Gibson, Elmar M. Merkle and Kim L. R. Brouwer and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

A. Benjamin Suttle

36 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Benjamin Suttle United States 21 744 706 636 257 186 36 1.5k
Dale Miles United States 23 635 0.9× 575 0.8× 663 1.0× 164 0.6× 145 0.8× 70 1.6k
Bertrand Billemont France 19 423 0.6× 658 0.9× 596 0.9× 246 1.0× 163 0.9× 39 1.4k
G. Veerman Netherlands 20 1.1k 1.5× 730 1.0× 635 1.0× 236 0.9× 147 0.8× 52 1.9k
Steven D. Reich United States 26 787 1.1× 532 0.8× 1.0k 1.6× 353 1.4× 261 1.4× 73 2.3k
Remy B. Verheijen Netherlands 18 630 0.8× 794 1.1× 542 0.9× 182 0.7× 213 1.1× 50 1.4k
Weiwei Tan United States 20 1.0k 1.4× 1.2k 1.7× 809 1.3× 232 0.9× 98 0.5× 59 1.9k
Roger Keresztes United States 19 1.1k 1.5× 631 0.9× 655 1.0× 456 1.8× 120 0.6× 37 2.7k
Yazdi K. Pithavala United States 25 1.1k 1.5× 1.2k 1.7× 1.2k 1.8× 581 2.3× 213 1.1× 65 2.5k
Peter Stopfer Germany 28 1.5k 2.0× 1.4k 2.0× 878 1.4× 191 0.7× 162 0.9× 69 2.6k
Stephen Shibata United States 28 1.2k 1.6× 601 0.9× 433 0.7× 226 0.9× 275 1.5× 84 2.2k

Countries citing papers authored by A. Benjamin Suttle

Since Specialization
Citations

This map shows the geographic impact of A. Benjamin Suttle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Benjamin Suttle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Benjamin Suttle more than expected).

Fields of papers citing papers by A. Benjamin Suttle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Benjamin Suttle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Benjamin Suttle. The network helps show where A. Benjamin Suttle may publish in the future.

Co-authorship network of co-authors of A. Benjamin Suttle

This figure shows the co-authorship network connecting the top 25 collaborators of A. Benjamin Suttle. A scholar is included among the top collaborators of A. Benjamin Suttle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Benjamin Suttle. A. Benjamin Suttle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suttle, A. Benjamin, Howard Ball, Mathiéu Molimard, et al.. (2014). Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. British Journal of Cancer. 111(10). 1909–1916. 147 indexed citations
2.
Suttle, A. Benjamin, Kenneth F. Grossmann, Danièle Ouellet, et al.. (2014). Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib. The Journal of Clinical Pharmacology. 55(4). 392–400. 41 indexed citations
3.
Tan, Antoinette R., Afshin Dowlati, Mark N. Stein, et al.. (2014). Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. British Journal of Cancer. 110(11). 2647–2654. 15 indexed citations
4.
Bennouna, Jaafar, Marion Deslandres, Hélène Senellart, et al.. (2014). A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Investigational New Drugs. 33(1). 138–147. 22 indexed citations
5.
Reardon, David A., Morris D. Groves, Patrick Y. Wen, et al.. (2013). A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. Clinical Cancer Research. 19(4). 900–908. 91 indexed citations
6.
Heath, Elisabeth I., Jeffrey R. Infante, Lionel D. Lewis, et al.. (2013). A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 71(3). 565–573. 29 indexed citations
7.
McLaughlin, Megan, Jason S. Slakter, Michael Tolentino, et al.. (2013). Initial Exploration of Oral Pazopanib in Healthy Participants and Patients With Age-Related Macular Degeneration. JAMA Ophthalmology. 131(12). 1595–1595. 24 indexed citations
8.
Hamberg, Paul, Winette T.A. van der Graaf, Peter de Bruijn, et al.. (2013). Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study. British Journal of Cancer. 110(4). 888–893. 16 indexed citations
9.
Bonate, Peter L. & A. Benjamin Suttle. (2013). Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 72(1). 231–240. 17 indexed citations
10.
Dy, Grace K., Jeffrey R. Infante, Sabine Eckhardt, et al.. (2012). Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Investigational New Drugs. 31(4). 891–899. 4 indexed citations
11.
Jonge, Maja J.A. de, Paul Hamberg, Jaap Verweij, et al.. (2012). Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Investigational New Drugs. 31(3). 751–759. 29 indexed citations
12.
Deng, Yanli, et al.. (2012). Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 43(5). 443–453. 72 indexed citations
13.
Heath, Elisabeth I., Lisa Malburg, Shelby D. Gainer, et al.. (2011). A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Investigational New Drugs. 30(4). 1566–1574. 33 indexed citations
14.
Heath, Elisabeth I., E. Gabriela Chiorean, Christopher J. Sweeney, et al.. (2010). A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors. Clinical Pharmacology & Therapeutics. 88(6). 818–823. 85 indexed citations
15.
16.
Frentzas, Sophia, Morris D. Groves, Jorge Barriuso, et al.. (2009). Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. Journal of Clinical Oncology. 27(15_suppl). 2040–2040. 9 indexed citations
17.
Lush, Richard M., Jeannine S. McCune, Leticia Tetteh, et al.. (2005). The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 56(6). 578–584. 24 indexed citations
18.
Song, Minho, et al.. (2000). Comparison of Zafirlukast (Accolate®) Absorption After Oral and Colonic Administration in Humans. Pharmaceutical Research. 17(2). 154–159. 21 indexed citations
19.
Suttle, A. Benjamin & Kim L. R. Brouwer. (1995). Gastrointestinal Transit and Distribution of Ranitidine in the Rat. Pharmaceutical Research. 12(9). 1316–1322. 9 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dale Miles Breakdown of academic impact, for papers by Bertrand Billemont Breakdown of academic impact, for papers by G. Veerman Breakdown of academic impact, for papers by Steven D. Reich Breakdown of academic impact, for papers by Remy B. Verheijen Breakdown of academic impact, for papers by Weiwei Tan Breakdown of academic impact, for papers by Roger Keresztes Breakdown of academic impact, for papers by Yazdi K. Pithavala Breakdown of academic impact, for papers by Peter Stopfer Breakdown of academic impact, for papers by Stephen Shibata
Rankless by CCL
2026